Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening.

The Journal of clinical endocrinology and metabolism - 1 Feb 2013

Machens Andreas, Lorenz Kerstin, Dralle Henning

Abstract excerpt

CONTEXT: In multiple endocrine neoplasia type 2, American Thyroid Association (ATA) management guidelines recommend continuous biochemical screening for pheochromocytoma and/or primary hyperparathyroidism. This implicit assumption of linear tumor development is difficult to reconcile with current...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Gland Neoplasms
Share to Adrenalectomy
Share to Age Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Hyperparathyroidism, Primary

Share to Infant

Share to Multiple Endocrine Neoplasia Type 2a

Share to Pheochromocytoma

Source

Identifiers

PMID: 23284010
DOI: 10.1210/jc.2012-3192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23284010-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening.PMID 23284010Read ↗

Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 2A in Denmark 1930–2021: A Nationwide Population-Based Retrospective StudySemantic proximity Read ↗

Multiple endocrine neoplasia type 2: achievements and current challenges.Semantic proximity Read ↗

100-Year evolution of precision medicine and surgery for multiple endocrine neoplasia type 2A.Semantic proximity Read ↗

Advances in risk-oriented surgery for multiple endocrine neoplasia type 2Semantic proximity Read ↗

Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?Semantic proximity Read ↗

An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2Semantic proximity Read ↗

The Changing Face of Multiple Endocrine Neoplasia 2A: From Symptom-Based to Preventative MedicineSemantic proximity Read ↗

Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies.Semantic proximity Read ↗

Clinical presentation of MEN 2A in index vs. non-index patients.Semantic proximity Read ↗

Genotype-specific development of MEN 2 constituent components in 683 RET carriers.Semantic proximity Read ↗

Molecular profiling in primary hyperparathyroidism.Semantic proximity Read ↗

DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.